Investigating how Wnt signaling can help treat glaucoma caused by glucocorticoids
The role of Wnt signaling in treating glucocorticoid-induced glaucoma
This study is looking at how a specific signaling process in the body might help prevent eye pressure from rising in people with glaucoma who are using common anti-inflammatory medications, with the hope of finding better treatment options that keep the benefits of these medications without causing eye problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10912747 on NIH RePORTER |
What this research studies
This research focuses on understanding how Wnt signaling can inhibit glaucoma that is induced by glucocorticoids, a common treatment for inflammation. The researchers will explore the mechanisms by which Wnt signaling affects ocular hypertension and its interaction with glucocorticoid receptors. Using mouse models, they will assess whether activating Wnt signaling can prevent the increase in eye pressure associated with glucocorticoid use while preserving its anti-inflammatory benefits. The ultimate goal is to develop new treatment strategies for glaucoma that do not compromise the effectiveness of glucocorticoids.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of glucocorticoid-induced glaucoma, particularly those with primary open-angle glaucoma.
Not a fit: Patients who do not use glucocorticoids or have other forms of glaucoma unrelated to glucocorticoid treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for glaucoma that effectively manage eye pressure without losing the anti-inflammatory effects of glucocorticoids.
How similar studies have performed: Previous studies have shown promise in using Wnt signaling pathways to influence ocular conditions, suggesting that this approach may yield beneficial results.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Mao, Weiming — Indiana University Indianapolis
- Study coordinator: Mao, Weiming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.